Veterinary compositions for use in treating mastitis, and associated methods
The present disclosure relates generally to sol-gel polymer composites that comprise chitosan, a hydrophilic polymer, a polysiloxane, and a gelation agent in a suitable medium. Advantageously, the sol-gel polymer composite can form a durable seal or strong solid in response to one or more physiological stimulus. The disclosure further relates to medical and veterinary uses of the composite, particularly, methods and delivery systems for reducing or preventing the incidence of a mammary disorder in a dairy animal. More particularly, the disclosure includes methods and sol-gel polymer composite compositions for creating a physical barrier on the teat surface or in the teat canal or cistern of a non-human animal for prophylactic treatment of mammary disorders such as mastitis wherein the sol-gel polymer creates a seal in response to one or more physiological stimulus.
1. A product for preventing or treating a mammary disorder in a female non-human animal, the product comprising an effective amount of a sol-gel polymer composite comprising chitosan, a hydrophilic polymer separate from chitosan, a gelation agent, a suitable medium, and a polysiloxane;
wherein the polysiloxane is present in an amount of about 30-70% by weight;
wherein the sol-gel polymer composite is configured to undergo a liquid-solid phase transition in response to one or more physiological stimuli arising from contact of the sol-gel polymer composition with a mammalian subject to form the product as a strong solid being evidenced by having an elastic modulus (G′) of about 450 Pa to about 10,000 Pa;
wherein the one or more physiological stimuli is selected from the group consisting of breast milk, udder secretions, or combinations thereof;
wherein the liquid-solid phase transition is reversible; and
wherein the gelation agent is configured to undergo physical crosslinking in response to the one or more stimuli.
2. The product according to claim 1 , wherein the medium is aqueous acetic acid.
3. The product according to claim 1 , wherein the chitosan is acylated.
4. The product according to claim 1 , wherein the polysiloxane is dimethylpolysiloxane (PDMS).
5. The product according to claim 1 , wherein the hydrophilic polymer is a water-soluble polysaccharide.
6. The product according to claim 5 , wherein the water-soluble polysaccharide is cellulose or a derivative thereof.
7. The product according to claim 1 , wherein the hydrophilic polymer is selected from the group consisting of methylcellulose, polyvinyl acetate, polyvinyl acetate-acylate, hydroxypropylcellulose, hydroxypropyl methylcellulose, ethyl hydroxylethyl cellulose, hypromellose acetate succinate, hyaluronic acid, nomomc triblock copolymer, polyethyleneglycol, sodium alginate and gelatin.
8. The product according to claim 1 , wherein the gelation agent is a salt selected from the group consisting of -Glycerophosphate disodium hydrate, -Glycerophosphate disodium pentahydrate, sodium pyrophosphate tetrabasic, potassium phosphate dibasic trihydrate, sodium hexametaphosphate, sodium tetrapolyphosphate, sodium hexapolyphosphate, sodium heptapolyphosphate, sodium octapolyphosphate, sodium tripolyphosphate and sodium polyphosphate, potassium ferricyanide and a mixture thereof.
9. The product according to claim 1 , wherein the gelation agent is an ionic crosslinking agent selected from the group consisting of lipophilic phosphates, plasticizers, anionic surfactants, gums, pectin, carrageenan (iota, kappa, and lambda), alginate, cyclodextrins, and a mixture thereof.
10. The product according to claim 1 , wherein the sol-gel polymer composite further comprises one or more antimicrobial agents.
11. The product according to claim 10 , wherein the antimicrobial agent is selected from the group consisting of a macrolide, a cephalosporin, a lincosaminide antibiotic, a fluoroquinolone, a tetracycline, a penicillin, a spectinomycin, a sulfonamide, a chloramphenicol, a fluorinated synthetic analog of thiamphenicol and a mixture thereof.
12. The product according to claim 11 , wherein the antimicrobial agent is a cephalosporin and the cephalosporin is ceftiofur hydrochloride.
13. A method of preventing or treating a mammary disorder in a female non-human animal, comprising administering an effective amount of the sol-gel polymer composite of any of claims 1-9 and 10-12 to a teat, a teat canal or a teat cistern of the animal.
14. A system for forming a physical barrier in the teat canal or cistern of a non-human animal for the prevention or treatment of a mammary disorder wherein the system comprises a delivery device containing the sol-gel polymer composite of any of claims 1-9 and 10-12.
15. A product for preventing or treating a mammary disorder in a female non-human animal, the product comprising an emulsion formed of:
about 55% to about 90% by volume (based on the total volume of the product) of a sol-gel polymer composite comprising chitosan, a hydrophilic polymer separate from chitosan, a gelation agent, a suitable medium, and a polysiloxane;
wherein the polysiloxane is present in an amount of about 30-70% by weight; and
about 10% to about 45% by weight (based on the total weight of the product) of an oil;
wherein the sol-gel polymer composite is configured to undergo a liquid-solid phase transition in response to one or more physiological stimuli, wherein the one or more physiological stimuli is selected from the group consisting of breast milk, udder secretions, or combinations thereof;
wherein the liquid-solid phase transition is reversible; and
wherein the gelation agent is configured to undergo physical crosslinking in response to the one or more stimuli.